NCI-H69/LX4

Analysis of acquired drug-resistance, study of small cell lung cancer

Human Caucasian small cell lung carcinoma, drug-resistant

NCI-H69/LX4 has been established by exposure of the parent line, H69 (Sigma Catalogue number. 91091802) to doxorubicin, also known as adriamycin. The line hyperexpresses P-glycoprotein and demonstrates a multidrug resistant drug accumulation deficit. It is recommended to culture the cells without drug after resuscitation until the first passage.

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 12
D16S539: 11
D5S818: 11,13
D7S820: 9
THO1: 8,9
TPOX: 10
vWA: 16,17

RPMI + 2mM Glutamine + 0.4μg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).

Split sub-confluent cultures (70-80%) by repeated pipetting of aggregates or scraping; 5% CO₂; 37°C

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.